<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0"><channel><title><![CDATA[Lift Therapeutics]]></title><description><![CDATA[Lift Therapeutics]]></description><link>https://www.lift-tx.com/news</link><generator>RSS for Node</generator><lastBuildDate>Wed, 23 Sep 2026 17:49:41 GMT</lastBuildDate><atom:link href="https://www.lift-tx.com/blog-feed.xml" rel="self" type="application/rss+xml"/><item><title><![CDATA[Lift Therapeutics Appoints Daniel Passeri as Chief Executive Officer]]></title><description><![CDATA[Veteran biotechnology executive, Daniel Passeri brings more than three decades of experience in oncology and immunotherapy drug development Interim CEO Dr. Bo Rode Hansen resumes role as member of the Board of Directors of Lift Therapeutics and assumes role as President - London, September 23, 2026 –  Lift Therapeutics (‘Lift’ or ‘the Company’) today announced the appointment of Daniel Passeri, MSc, JD, as Chief Executive Officer (CEO). Mr. Passeri brings over 30 years of experience in...]]></description><link>https://www.lift-tx.com/post/lift-therapeutics-appoints-daniel-passeri-as-chief-executive-officer</link><guid isPermaLink="false">6ab2eaf509ec856a564d3399</guid><pubDate>Wed, 23 Sep 2026 09:00:07 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/ee000d_4443888a716c4d789fb7ad5bcb1bafec~mv2.png/v1/fit/w_586,h_562,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Matthew Thornton</dc:creator></item><item><title><![CDATA[Queen Mary University of London and LIfT BioSciences ‘KTP’ Project Earns Prestigious “Outstanding” Rating]]></title><description><![CDATA[Innovate UK Knowledge Transfer Partnerships (KTPs) connect businesses with academic expertise to turn innovative ideas into real-world impact. The KTP is a collaboration between a postgraduate (Associate), a business, and a university (Knowledge Base, this involves the Principal investigators and Knowledge base office).  The KTP between Queen Mary University of London (QMUL) and LIfT Biosciences has been awarded the highest possible “Outstanding” rating and a Certificate of Excellence from...]]></description><link>https://www.lift-tx.com/post/queen-mary-university-of-london-and-lift-biosciences-ktp-project-earns-prestigious-outstanding-r</link><guid isPermaLink="false">6aa05ee990d669856e82f245</guid><pubDate>Wed, 17 Jun 2026 10:46:46 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/755ced_088af14878cd4f02af09837dbe816865~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT Biosciences Establishes Scientific Advisory Board to Accelerate Development of Neutrophil-based Cancer Therapies]]></title><description><![CDATA[-       Members include Nobel laureate James P. Allison, Padmanee Sharma, Taha Merghoub, and Kingston Mills, who are all globally renowned experts in cancer immunotherapy and translational cancer immunology -       LIfT BioSciences’ lead IMAN-based drug candidate is a groundbreaking next-generation immunotherapy designed to treat patients with treatment-resistant cancers London, May 07, 2026 – LIfT BioSciences (‘LIfT’ or ‘the Company’) today announced the formation of its Scientific Advisory...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-establishes-scientific-advisory-board-to-accelerate-development-of-neutrophil-based</link><guid isPermaLink="false">6aa05ee990d669856e82f224</guid><pubDate>Thu, 07 May 2026 10:00:16 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/755ced_c48c53300a384e1c9d88e1c1b120a9b7~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT BioSciences Announces Publication of Review Article in Frontiers in Immunology Highlighting Broad Therapeutic Potential of Neutrophils and IMANs in Cancer ]]></title><description><![CDATA[Neutrophils, long considered short-lived immune cells, can be therapeutically targeted when their appropriate subset and functional state are identified for the disease context LIfT BioSciences’ immuno-modulatory alpha neutrophils (IMANs) are designed to have the potent anti-tumour activity of naturally occurring N1 neutrophils fixed into their biology London, April 22, 2026 – LIfT BioSciences (‘LIfT’ or ‘the Company’) today announced the publication of an article in Frontiers in Immunology...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-announces-publication-of-review-article-in-frontiers-in-immunology-highlighting-bro</link><guid isPermaLink="false">6aa05ee990d669856e82f219</guid><pubDate>Wed, 22 Apr 2026 14:00:33 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/755ced_88b9c9129b2441afad758e7974ee1380~mv2.png/v1/fit/w_965,h_965,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT BioSciences Announces CEO Transition to Drive Next Phase of Growth with Neutrophil-based Therapies]]></title><description><![CDATA[- Dr. Bo Rode Hansen, current Board member and Corporate Development Officer named Interim CEO - Alex Blyth, Founder and CEO to step down and will continue to work with the Company at a Board level - LIfT BioSciences is currently advancing its first IMAN-based product and preparing to initiate a first-in-human Phase 1 clinical trial. This groundbreaking next-generation immunotherapy aims to target patients with treatment-resistant cancers. London, January 7, 2026  – LIfT BioSciences (‘LIfT’...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-announces-ceo-transition-to-drive-next-phase-of-growth-with-neutrophil-based-therap</link><guid isPermaLink="false">6aa05ee990d669856e82f234</guid><pubDate>Wed, 07 Jan 2026 10:00:17 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/755ced_1f050699d20c422ca398bfc73bf00c20~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT BioSciences to present preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at the 40th Society for Immunotherapy of Cancer]]></title><description><![CDATA[London, 5 November 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil immunotherapies, today announces that preclinical data demonstrating the potential of its first-in-class Immunomodulatory Alpha Neutrophils (IMANs) to restore innate immune competence and remodel the tumour microenvironment (TME) in support of anti-tumor immunity, will be presented in a poster at the 40th Society for Immunotherapy of Cancer being held from 5-9...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-to-present-preclinical-data-on-its-first-in-class-immunomodulatory-alpha-neutrophil</link><guid isPermaLink="false">6aa05ee990d669856e82f20c</guid><pubDate>Thu, 06 Nov 2025 09:15:02 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/c80ff1_61b49a12f39f45e492c742ef25ec30ee~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT BioSciences announces grant of €12 million from Ireland’sDisruptive Technologies Innovation Fund to support the first-in-human clinical trial of LIfT’s IMAN therapy]]></title><description><![CDATA[Galway, London, 29 July 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-announces-grant-of-12-million-from-ireland-sdisruptive-technologies-innovation-fun</link><guid isPermaLink="false">6aa05ee990d669856e82f248</guid><pubDate>Tue, 29 Jul 2025 06:00:15 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/c80ff1_a8b249d71977450aaedfaa56a528ea99~mv2.png/v1/fit/w_973,h_545,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT BioSciences Expands U.S. Footprint with New Facility at Portal Innovations, Houston Helix Park]]></title><description><![CDATA[London, 25 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-expands-u-s-footprint-with-new-facility-at-portal-innovations-houston-helix-park</link><guid isPermaLink="false">6aa05ee990d669856e82f225</guid><pubDate>Wed, 25 Jun 2025 06:00:18 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/f1bf1f_684a63fc87844e778e706ecce18a6485~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT BioSciences joins Bayer Co.Lab Cambridge, securing access to cutting-edge lab facilities]]></title><description><![CDATA[London, 4 June 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-joins-bayer-co-lab-cambridge-securing-access-to-cutting-edge-lab-facilities</link><guid isPermaLink="false">6aa05ee990d669856e82f23d</guid><pubDate>Wed, 04 Jun 2025 06:00:02 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/c80ff1_755ff5a2092f46be980cf2f7262e0e71~mv2.png/v1/fit/w_600,h_400,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[Our Chairman Tony de Fougerolles discusses innate immune rejuvenation]]></title><description><![CDATA[Chairman of LIfT BioSciences, to explore the concept of innate immune rejuvenation – a central pillar of our approach to overcoming...]]></description><link>https://www.lift-tx.com/post/our-chairman-tony-de-fougerolles-discusses-innate-immune-rejuvenation</link><guid isPermaLink="false">6aa05ee990d669856e82f211</guid><pubDate>Wed, 28 May 2025 15:36:18 GMT</pubDate><enclosure url="http://video.wixstatic.com/video/c80ff1_4a822bc67dfc440990d8509b221178d7/1080p/mp4/file.mp4" length="0" type="video"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT BioSciences presents preclinical data on its first-in-class Immunomodulatory Alpha Neutrophils at American Society of Gene &#38; Cell Therapy 28th Annual Meeting]]></title><description><![CDATA[showcasing its versatility in diseases beyond oncology London, 22   May 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-presents-preclinical-data-on-its-first-in-class-immunomodulatory-alpha-neutrophils</link><guid isPermaLink="false">6aa05ee990d669856e82f247</guid><pubDate>Thu, 22 May 2025 06:00:18 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/c80ff1_beb1ee0bb3974548a2ac65a0f2d9debb~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT BioSciences presents latest data on its first-in-class Immunomodulatory Alpha Neutrophils at International Society for Cell and Gene Therapy]]></title><description><![CDATA[London, 19 May 2025– LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-presents-latest-data-on-its-first-in-class-immunomodulatory-alpha-neutrophils-at-in</link><guid isPermaLink="false">6aa05ee990d669856e82f246</guid><pubDate>Mon, 19 May 2025 06:00:11 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/c80ff1_c2daf462150d45b9a1d0da1ac7c6919f~mv2.png/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT BioSciences announces partnership with University of Galway for clinical trial in Ireland]]></title><description><![CDATA[London , 28 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-announces-partnership-with-university-of-galway-for-clinical-trial-in-ireland</link><guid isPermaLink="false">6aa05ee990d669856e82f213</guid><pubDate>Mon, 28 Apr 2025 06:00:12 GMT</pubDate><enclosure url="http://vimeo.com/1078689814/2988296bdd?ts=0&amp;share=copy" length="0" type="video"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[Professor John Campbell PhD FRSB shares insights into how treatment resistance in solid tumours can be overcome]]></title><description><![CDATA[We spoke to Professor John Campbell PhD FRSB, a member of our Scientific Advisory Board, to discuss a key question in oncology: How can treatment resistance in solid tumours be overcome?]]></description><link>https://www.lift-tx.com/post/professor-john-campbell-phd-frsb-shares-insights-into-how-treatment-resistance-in-solid-tumours-can</link><guid isPermaLink="false">6aa05ee990d669856e82f24c</guid><pubDate>Thu, 24 Apr 2025 09:33:17 GMT</pubDate><enclosure url="http://video.wixstatic.com/video/0be6df_b7a3d2ecdcba45f2a84791a7878068f6/1080p/mp4/file.mp4" length="0" type="video"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[Dr. Mark A. Exley shares what excites him most about joining LIfT as Chief Scientific Officer and the potential of LIfT’s technology]]></title><description><![CDATA[In this video, Dr. Mark A. Exley shares his background in biotech, what makes our neutrophil-based approach to cancer therapy so...]]></description><link>https://www.lift-tx.com/post/dr-mark-a-exley-shares-what-excites-him-most-about-joining-lift-as-chief-scientific-officer-and-th</link><guid isPermaLink="false">6aa05ee990d669856e82f244</guid><pubDate>Tue, 08 Apr 2025 13:45:58 GMT</pubDate><enclosure url="http://video.wixstatic.com/video/0be6df_947322ade3ba4db6957abb08cbdbb8f2/1080p/mp4/file.mp4" length="0" type="video"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT BioSciences Appoints Mark A. Exley as Chief Scientific Officer]]></title><description><![CDATA[Mark brings 30 years of experience in R&#38;D spanning discovery to late-stage clinical development London, 7 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and world leader in neutrophil immuno-therapies, today announces the appointment of Mark A. Exley, PhD as Chief Scientific Officer (CSO), effective 7 April. The appointment of a CSO with extensive clinical expertise comes at a pivotal time for LIfT, as the Company prepares for clinical trials of its...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-appoints-mark-a-exley-as-chief-scientific-officer</link><guid isPermaLink="false">6aa05ee990d669856e82f210</guid><pubDate>Mon, 07 Apr 2025 06:00:20 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/0be6df_33fbe27fd324417c9fd9e7b8b43453d4~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[Dr Michael McCarthy discusses one of the biggest challenges in solid tumour treatment: treatment resistance]]></title><description><![CDATA[We spoke to  Dr Michael McCarthy, Consultant Medical Oncologist at University Hospital Galway, regarding what treatment resistance in...]]></description><link>https://www.lift-tx.com/post/dr-michael-mccarthy-discusses-one-of-the-biggest-challenges-in-solid-tumour-treatment-treatment-res</link><guid isPermaLink="false">6aa05ee990d669856e82f23c</guid><pubDate>Thu, 03 Apr 2025 15:58:15 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/0be6df_16a4df529fca41f7b87c465075c1bef9~mv2.jpg/v1/fit/w_400,h_250,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT BioSciences gains access to half a million allogeneic donors through collaboration with Gift of Life Biologics]]></title><description><![CDATA[Access to extensive donor pool supports LIfT’s move into the clinic London, 03 April 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’),...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-gains-access-to-half-a-million-allogeneic-donors-through-collaboration-with-gift-of</link><guid isPermaLink="false">6aa05ee990d669856e82f215</guid><pubDate>Thu, 03 Apr 2025 07:14:32 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/0be6df_1ebb541578c64b919dceb72619150ae4~mv2.png/v1/fit/w_750,h_500,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[Our CEO Alex Blyth discusses what makes LIfT’s IMANs different]]></title><description><![CDATA[To kick LIfT’s science series off, we spoke to our CEO Alex Blyth regarding what makes IMANs different to regular neutrophils, what were...]]></description><link>https://www.lift-tx.com/post/our-ceo-alex-blyth-discusses-what-makes-lift-s-imans-different</link><guid isPermaLink="false">6aa05ee990d669856e82f226</guid><pubDate>Thu, 20 Mar 2025 16:39:10 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/c80ff1_552e050c405c4b71bafd0dde25ae8c81~mv2.jpg/v1/fit/w_1000,h_1000,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item><item><title><![CDATA[LIfT BioSciences Secures Another Landmark US Patent, Strengthening Its Position as the World Leader in Neutrophil Immunotherapies]]></title><description><![CDATA[London, 13 March 2025 – LIfT BioSciences, (‘LIfT’ or ‘the Company’), a rapidly emerging biotech and the global leader in neutrophil...]]></description><link>https://www.lift-tx.com/post/lift-biosciences-secures-another-landmark-us-patent-strengthening-its-position-as-the-world-leader</link><guid isPermaLink="false">6aa05ee990d669856e82f22a</guid><pubDate>Thu, 13 Mar 2025 07:00:12 GMT</pubDate><enclosure url="https://static.wixstatic.com/media/c80ff1_81360ce53c144739b48e56ad14799a79~mv2.png/v1/fit/w_1000,h_862,al_c,q_80/file.png" length="0" type="image/png"/><dc:creator>Vladislava </dc:creator></item></channel></rss>